Granulocyte-macrophage colony-stimulating factor treatment before doxorubicin and cyclophosphamide chemotherapy priming in women with early- stage breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 11, 1999, Pages 3426-3430

  Kobrinsky, Nathan L ^a   Sjolander, Diane E ^a   Cheang, Mary S ^a   Levitt, Ralph ^a   Steen, Preston D ^a  

^a MeritCare Roger Maris Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0032754337     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.11.3426     Document Type: Article

References (16)

1. Demetri GD, Anderson KC: Bone marrow failure, in Abeloff MD, Armitagè JO, Lichter AS, Niederhuber JE (eds): Clinical Oncology, New York, NY, Churchill Livingstone Inc, 1995, pp 433-456
2. Bonadonna G: Conceptual and practical advances in the management of breast cancer. Cancer 7:1380-1397, 1989
3. Hryniuk WM: Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14:63-74, 1987
4. Dodwell DJ, Gurney H, Thatcher N: Dose intensity in cancer chemotherapy. Br J Cancer 61:787-797, 1990
5. Piguet D, Chapuis B: Recombinant human granulocyte-macrophage colony-stimulating factor in acquired or chemotherapy-induced neutropenia. Acta Oncol 33:639-643, 1994
6. Mayordomo JI, Rivera F, Diaz-Puente MT, et al: Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Nat Cancer Inst 87:803-808, 1995
7. Hansen F, Stenbyguard L, Skovsgaard T: Effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hematologic toxicity induced by high-dose chemotherapy in patients with metastatic breast cancer. Acta Oncol 34:919-924, 1995
8. Bregni M, Siena S, Di Nicola M, et al: Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte-colony stimulating factor after high-dose cyclophosphamide cancer therapy. J Clin Oncol 14:628-635, 1996
9. Vadhan-Raj S, Broxmeyer H, Hittelman W, et al: Two possible mechanisms for the abrogation of chemotherapy (CT)-induced myelosuppression by GM-CSF: Increased myeloid mass and non-cycling progenitors. Blood 76:170a, 1990 (abstr 670)
10. Vadhan-Raj S, Broxmeyer H, Hittelman W, et al: Abrogating chemotherapy (CT)-induced myelosuppression by GM-CSF: Optimizing the schedule. Proc Am Soc Clin Oncol 10:349, 1991 (abstr 1241)
11. Vadhan-Raj S, Broxmeyer H, Hittelman W, et al: Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: Protection at the progenitor cell level. J Clin Oncol 10:1266-1277, 1992
12. Aglietta M, Monzeglio C, Pasquino P, et al: Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs. Cancer 72:2970-2973, 1993
13. Edmonson J, Hartmann L, Long H, et al: Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule and route of administration in patients receiving cyclophosphamide and carboplatin. Cancer 70:2529-2539, 1991
14. Bernstein S, Christiansen N, Fay J, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: A pilot trial. Exp Hematol 24:1363-1368, 1996
15. Schwartzberg L, West W, Birch R, et al: Randomized prospective trial ± pretreatment with GM-CSF prior to high-dose cyclophosphamide, etoposide and cisplatin plus G-CSF. Proc Am Soc Clin Oncol 12:452, 1993 (abstr 1568)
16. Jones S, Schottstaedt M, Duncan L, et al: Randomized doubleblind prospective trial to evaluate the effects of Sargramostim verses placebo in a moderate-dose flurouracil, doxorubicin and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol 14:2976-2983, 1996